Limited (LON:HCM – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 274.45 ($3.38) and traded as low as GBX 232.04 ...

The U.S. FDA is to temper the alert it put out in November 2023 pointing to a potential risk of CAR T therapies causing de novo malignancies. “There was this issue of possible safety concerns with T ...

January 15, 2025, 14:24 pm ET, BY Rick O.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short HCM slightly ...

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Chinese biopharma Hutchmed today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

Hutchmed (HCM) announces that the supplemental new drug application for Orpathys has been granted approval by the China National Medical Products Administration, or NMPA, for the treatment of adult ...

ISTANBUL, Turkey, Jan. 13, 2025 (GLOBE NEWSWIRE) -- As the demand for cosmetic surgery continues to surge worldwide, Dr. Safa ...

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US for the treatment of adult patients ...

Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison ...